




RealRate

PHARMACEUTICAL 2022

GYRE Therapeutics INC
Rank 387 of 471

CATALYST
BIOSCIENCES



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of GYRE Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GYRE Therapeutics INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 9.0% points. The greatest weakness of GYRE Therapeutics INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 128% points.

The company's Economic Capital Ratio, given in the ranking table, is 146%, being 129% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	51,476
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,165
Liabilities, Non-Current	408
Other Assets	3,216
Other Compr. Net Income	-5.0
Other Expenses	7,380
Other Liabilities	0
Other Net Income	-39
Other Revenues	7,338
Property and Equipment	970
Research and Development	68,889
Selling, General and Administrative Expense	18,963

Output Variable	Value in 1000 USD
Assets	55,662
Liabilities	14,573
Expenses	95,232
Revenues	7,338
Stockholders Equity	41,089
Net Income	-87,933
Comprehensive Net Income	-87,936
BaseVar	86,424
ECR before LimitedLiability	4.7%
Economic Capital Ratio	146%